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Abstract
High consumption of whole-grain food such as oats is associated with a reduced risk of CVD and type 2 diabetes. The present study aimed
to systematically review the literature describing long-term intervention studies that investigated the effects of oats or oat bran on CVD risk
factors. The literature search was conducted using Embase, Medline and the Cochrane library, which identified 654 potential articles.
Seventy-six articles describing sixty-nine studies met the inclusion criteria. Most studies lacked statistical power to detect a significant
effect of oats on any of the risk factors considered: 59% of studies had less than thirty subjects in the oat intervention group. Out of
sixty-four studies that assessed systemic lipid markers, thirty-seven (58%) and thirty-four (49%) showed a significant reduction in total
cholesterol (2–19% reduction) and LDL-cholesterol (4–23% reduction) respectively, mostly in hypercholesterolaemic subjects. Few studies
(three and five, respectively) described significant effects on HDL-cholesterol and TAG concentrations. Only three out of twenty-five
studies found a reduction in blood pressure after oat consumption. None of the few studies that measured markers of insulin sensitivity
and inflammation found any effect after long-term oat consumption. Long-term dietary intake of oats or oat bran has a beneficial effect on
blood cholesterol. However, there is no evidence that it favourably modulates insulin sensitivity. It is still unclear whether increased oat
consumption significantly affects other risk markers for CVD risk, and comprehensive, adequately powered and controlled intervention
trials are required to address this question.
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High consumption of whole-grain foods is associated with a
reduced risk of chronic diseases including CHD(1,2), hyper-
tension(3) and type 2 diabetes(4,5). Suggested mechanisms of
action include reduction in serum lipid concentrations(6) and
blood pressure(7), increased insulin sensitivity(8) and reduction
in thrombotic and inflammatory markers(9,10). However, the
results of the two most comprehensive, well-designed ran-
domised control trials ever conducted with whole-grain
foods found no significant effects on the major risk factors
for CVD(7,11).
Whole grains consumed in a western diet consist mainly of
wheat, rye, maize and oats. These cereals have different
chemical compositions, which could explain the different
responses with regard to CVD risk markers. Research
has focused on b-glucan-rich cereals such as oats for their
potential effect on serum cholesterol concentration(12)
and postprandial glycaemia(13), with inconsistent results.
Although numerous studies suggest that there is a beneficial
effect of oat consumption on markers of CVD risk, there is
a need for a rigorous assessment of the strength of this
evidence. The present study aimed to systematically review
the literature describing intervention studies that had investi-
gated the effect of regular consumption of whole-grain
oat-based products (including oat bran) on risk factors for
CVD. The objectives of the study were (i) to summarise the
extensive literature on the subject, (ii) to describe the relative
strengths and weaknesses of the studies and (iii) to evaluate
the need for large intervention trials.
Methods
Literature search and study selection
The methods for the present literature review have been
previously described (Thies F, Masson LF, Boffetta P et al.,
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in this supplement). Briefly, Embase, Medline and the
Cochrane library (Cochrane Central Register of Controlled
Trials) were searched for articles describing intervention
studies with oat-based products published before 26
November 2012. A total of 1174 articles were identified
(Fig. 1). Titles and abstracts of 654 articles were reviewed
independently by two reviewers who agreed that the full
text should be obtained for 244 articles. A further 178 articles
were then excluded, following agreement by two
reviewers. Ten additional articles were identified by searching
the reference lists in relevant articles obtained from the
database search.
Data extraction
Data were extracted by one reviewer into pre-prepared tables
and the data extraction from a random 10% of articles was
checked and agreed by a second reviewer. The primary
outcomes of interest included blood lipids/lipoproteins,
blood pressure, glucose and insulin.
Quality of reporting and reporting preferences
Use of the Jadad scale for reporting randomised control trials(14)
to score the quality of reporting of each article, as well as the
criteria for classifying studies as randomised control trials, is
described elsewhere (Thies F, Masson LF, Boffetta P et al.,
in this supplement). For studies that showed a statistically
significant (P,0·05) effect of oats consumption, the percentage
change from baseline in the intervention group relative to the
control group was the preferred measure to present. If this
was not available in the article, it was calculated from the results
given, and such values are indicated in the tables. Interventions
that involved products with altered molecular weight of
b-glucan were not included.
Results
Study characteristics
We identified seventy-six articles(7,15–89) describing sixty-nine
studies that assessed the effect of oat consumption on CVD
Articles from reference
lists (n 10)
Potential articles
(n 244)
Excluded on full text              (n 178)
Full text not in english             n 5
Not an intervention                  n 16
Intervention not oats                n 10
OAT abbreviation                     n 1
Conference abstract                 n 7
Intervention less than 7 d        n 28
Effect of oats not clear             n 40
Outcomes not relevant            n 28
Not whole-grain oat                 n 35
Response to exercise               n 8
Relevant articles
(n 76)
Duplicate articles
(n 520)
Potential articles
(n 654)
Ovid medline(R)
(n 424)
Embase classic + Embase
(n 521)
Cochrane central register of
controlled trials (n 229)
Excluded on title/abstract    (n 410)
Children                                  n 41
Animals                                  n 3
Other cereal                           n 29
(Non-) oat cell carcinoma     n 94
OAT abbreviation                  n 141
Other                                      n 102
Combined databases
(n 1174)
Fig. 1. Flow diagram of article selection.
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risk factors (Fig. 1). Online Web Tables S1–S3 describe the
characteristics of these sixty-nine studies with less than thirty
subjects (forty-one studies, 59%), between thirty and
fifty-nine subjects (seventeen studies, 25%), and at least
sixty subjects (eleven studies, 16%) in the oat intervention
group, respectively. These tables are sub-grouped according
to the quality of reporting of the articles: forty-six articles
(61%) had a low quality of reporting, and thirty articles
(39%) had a high quality of reporting.
Over half (54%) of the studies were carried out in North
America (thirty-four in the USA and three in Canada). Six
studies were carried out in Australia, five in Sweden, four
each in the UK and New Zealand, three in Finland, two in
the Netherlands, and one each in Austria, France, Germany,
Denmark, China, Mexico and Brazil. One multicentre study
was carried out in sites in Canada, the UK and Australia.
Lipids
Tables 1–3 show the results of sixty-four studies that assessed
the blood lipid response to oat intervention in studies with
less than thirty subjects, thirty to fifty-nine subjects or at
least sixty subjects, respectively, in the oat intervention
group. Of these sixty-four studies, thirty-seven (58%) and
thirty-four (53%) studies identified a statistically significant
reduction in total cholesterol and LDL-cholesterol, respect-
ively, mostly in hypercholesterolaemic subjects; the rest of
the studies found no significant response. This significant
reduction ranged from 2 to 19% for total cholesterol and
from 4 to 23% for LDL-cholesterol. In the eleven studies
that contained at least sixty subjects in the oat intervention
group, a higher proportion of studies found significant
reductions in total cholesterol and LDL-cholesterol (eight
studies (73%) and seven studies (64%), respectively), but
the magnitude of these reductions was more conservative:
3–6% for total cholesterol and 4–8% for LDL-cholesterol
(Table 3).
Three studies found that oat consumption significantly
increased HDL-cholesterol levels by 4–11%. The ratios of
total cholesterol:HDL-cholesterol and of LDL-cholesterol:
HDL-cholesterol were reduced significantly in three studies
(by 2–7%) and in five studies (by 9–21%), respectively.
Five studies found a statistically significant reduction in TAG
concentrations (by 11–24%) following oat-based intervention.
There is currently no evidence that oat consump-
tion influences concentrations of HDL2 and HDL3
subfractions(18,45,49,83), intermediary density lipoprotein (IDL)
cholesterol(18), VLDL cholesterol(15,18,23,24,33,41,42,57,62,87), or
LDL, HDL or VLDL particle size(49).
Blood pressure
Table 4 shows that three(41,55,75) of twenty-five studies found
that oat consumption significantly reduced systolic blood
pressure by 4–6%. Two of these studies(41,55) had less than
thirty subjects in the oat intervention group. Pins et al.(75)
found that 73% of participants receiving treatment for
hypertension were able to stop or reduce their medication
by one-half after 6 weeks of consuming oats compared with
42% in the wheat-based cereal (control) group (P,0·05).
In addition, participants in the oat intervention group whose
medication was not reduced had a significant 4% decrease
in systolic blood pressure in comparison with the control
group. The other twenty-two studies found no significant
effect of oat consumption on systolic blood pressure.
Glucose and insulin
Blood glucose levels changed significantly in response to oat
consumption in five out of twenty-one studies (Table 5).
Glucose levels increased in three(37,51,59) of these studies
relative to the comparison group or baseline, and glucose
levels decreased in the other two studies(52,75). Four of these
five studies had less than thirty subjects in the oat intervention
group, and the other study, with n 45 in the oat intervention
group, found a 13% decrease in glucose after 12 weeks of
an oat-rich diet compared with the control group who
consumed wheat cereals(75).
Fifteen out of sixteen studies found no significant effect of
oats on insulin concentrations. One relatively small study
with twenty-two participants found that high-molecular
weight oat bran significantly increased insulin concentrations
by 23% compared with baseline(52). None of the studies that
measured glucose:insulin ratio(51), HbA1c(15,35), homeostasis
model assessment(7,41,66), quantitative insulin sensitivity
check index (QUICKI)(7), insulin sensitivity(41,49,50,55) or the
acute insulin response to glucose(49) found a significant
effect of oat consumption on these variables. One study
found that glucose effectiveness decreased in the oat interven-
tion group by 5% but increased in the wheat intervention
group by 19% (P¼0·03 for interaction)(49).
Other outcomes
None of the studies that measured C-reactive
protein(7,25,44,77,82,88), lipoprotein(a) (Lp(a))(28,79), fibrinogen(20)
or IL-6(7) found a significant effect of oat consumption on
these variables. There is also a lack of evidence for a beneficial
effect of oats on endothelial function(70–72).
One study(44) reported measuring plasma homocysteine and
found that concentrations were reduced by 16% in response
to 12 weeks of oat bran. A Danish study found that plasmi-
nogen activator inhibitor-I and factor VII levels decreased
significantly by 27 and 7%, respectively, following a 2-week
oat bran v. a low-fibre diet(33), but no other studies reported
measuring these outcomes. Another study measured serum
NEFA that increased by 19% after consuming 35–50 g/d of
oat bran for 4 weeks, relative to the group consuming an
oat bran-free diet(79).
Discussion
Lipids/lipoproteins
The present systematic review supports the results of obser-
vational studies suggesting that increased oat consumption
Oats and CVD risk markers S21
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Table 1. Oats and blood lipids (studies with ,30 subjects in the oat intervention group)
Cholesterol
Comparison Total LDL HDL Total:HDL LDL:HDL TAG Reference
Low reporting quality
Oat bran v. wheat bran NS NS NS – NS NS Abrahamsson et al.(15)
100 g/d oat bran v. control diet 19% # 23% # NS – – 19%* # Anderson et al.(16)
25 g/d oat bran v. baseline 5% # 9% # NS – – NS Anderson et al.(17)
Oat bran v. wheat bran 8%* # 7%* # NS – NS NS Anderson et al.(18),
Bridges et al.(19)
Oat bran v. wheat bran bread NS NS NS – – NS Bremer et al.(20)
28 g/d oatmeal v. 28 g/d farina NS NS NS – – NS Davidson et al.(21)
28 g/d oat bran v. 28g/d farina NS NS NS – – NS
56 g/d oatmeal v. 28 g/d farina NS NS NS – – NS
56 g/d oat bran v. 28g/d farina 10%* # 17%* # NS – – NS
84 g/d oatmeal v. 28 g/d farina 8%* # 11%* # NS – – NS
84 g/d oat bran v. 28g/d farina 8%* # 12%* # NS – – NS
LFLC v. LFLC and oat bran
v. oat bran v. processed oat bran
NS – NS NS – – Demark-Wahnefried
et al.(22)
50 g/d oat bran v. baseline 12% # – – 7%* # – –
40 g/d oat bran v. low-fibre diet NS NS NS – – NS Dubois et al.(23)
100 g/d oat bran v. rice bran NS NS NS – NS NS Hegsted et al.(24)
Oat bran bread v. strawberries NS NS NS NS – NS Jenkins et al.(25)
125 g/d rolled oats v. control diet NS – NS – – NS Judd & Truswell(26)
Oat bran muffins (immediate)
v. no oat bran muffins
NS NS NS NS – – Kahn et al.(27)
100 g/d oat bran v. baseline 8% # 10% # NS – – NS Kelley et al.(28)
Oat v. wheat (bread and cookies) NS NS NS NS – NS Kerckhoffs et al.(29)
Oat v. wheat (orange juice) 4% # 7% # NS 5% # – NS
100g/d oat bran v. baseline 13% # 14% # NS – – NS Kirby et al.(30)
Toasted oat bran v. control NS – – – – NS Kretsch et al.(31),
Calloway & Kretsch(32)
Untoasted oat bran v. control NS – – – – NS
Oat bran v. low-fibre diet 10%* # NS NS – – 12%* # Kristensen & Bugel(33)
Oat-based cereal v. wheat cereal NS NS NS – – NS Maki et al.(34)
100 g/d oat bran v. low-fibre diet 9%* # – – – – NS Marlett et al.(36)
Oat bran v. high-amylose starch NS NS NS – – 11%* # Noakes et al.(37)
Oat bran v. low-amylose starch NS NS NS – – 16%* #
0·75–1 l/d oat milk v. cow’s milk NS NS NS – – NS Onning et al.(38)
0·75–1 l/d oat milk v. soya milk NS NS NS – – NS
28 g/d oat bran v. no supplement NS NS 9%* " NS NS NS Robitaille et al.(39)
Oat bran v. wheat bran 18%* # 22%* # NS – 14%* # NS Romero et al.(40)
Oat bran v. psyllium NS NS NS – NS NS
45 g/d oats v. without 45 g/d oats 10%* # 12%* # NS – – NS Saltzman et al.(41)
77 g/d oat bran v. baseline 6% # 7%* # NS – – – Spiller et al.(42)
77 g/d oat bran v. 15g/d guar gum 5%* " 11%* " NS – – NS
50 g/d oat bran or oat-free diet NS NS – – – NS Stewart et al.(43)
150 g/d rolled oats v. baseline 5%* # 14% # NS – – NS Turnbull & Leeds(45)
Oat bran v. wheat bran 4% # 6% # NS – – NS Whyte et al.(46)
Oat bran v. wheat flour 9% # 12% # NS – – NS Zhang et al.(47)
High reporting quality
5–6 g/d oat bran b-glucan v. 8–9 g/d
oat bran b-glucan v. high fibre,
no oat bran b-glucan
NS NS NS – – NS Beck et al.(48)
Oatmeal and oat bran v. wheat-based cereal NS 11%* # NS NS 21%* # NS Davy et al.(49,50)
60 g/d oat cookies v. baseline NS – – – – NS Conceicao
de Oliveira et al.(51)
High MW oat bran v. baseline NS NS NS – NS NS Frank et al.(52)
Low MW oat bran v. baseline NS NS NS – NS NS
84 g/d oat bran v. rice starch 13%* # 13%* # NS – 14%* # NS Gerhardt & Gallo(53)
84 g/d oat bran v. rice bran NS NS NS – NS NS
34 g/d oat bran v. wheat bran and whole-
wheat flour or wheat bran, whole-wheat
flour and 17g/d oat bran combined
5%* # NS NS – – 15%* # Gold & Davidson(54)
Oat cereal v. low fibre cereal 11%* # 18%* # NS – – NS Keenan et al.(55)
Oat bran v. wheat bran 6% # 7%* # NS – – NS Kestin et al.(56)
Oat bran v. rice bran 4% # 5%* # NS – – NS
100g/d oat bran v. refined wheat NS NS NS – – – Swain et al.(57)
50 g/d oat bran v. baseline NS NS NS – – NS Uusitupa et al.(58,59)
LFLC, low-fat, low-cholesterol diet; MW, molecular weight.
*% change from baseline relative to comparison group estimated.
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has a beneficial effect on serum cholesterol concentration,
particularly in hypercholesterolaemic subjects. This is consist-
ent with Ripsin et al.’s(90) rigorous meta-analysis that con-
cluded that about 3 g/d of soluble fibre from oat products
can lower total cholesterol by 0·13 to 0·16mmol/l, with a
greater reduction in individuals with higher initial cholesterol
concentrations. A 1% reduction in total cholesterol or
LDL-cholesterol is associated with a 2–3% or 1% decreased
risk, respectively, of CHD(91). The magnitude of the effect
found in the present review (3–6% for total cholesterol and
4–8% for LDL-cholesterol when considering studies with a
sufficient sample size) would translate to a 6–18% decrease
in CHD risk, which would equate to a substantial health
benefit at a population level. However, increased oat
consumption does not seem to significantly benefit other
systemic lipid/lipoprotein markers associated with CVD risk,
such as serum TAG and HDL-cholesterol concentration.
Lipoprotein particle number and size, particularly for LDL,
are possibly strong predictors of CVD(92) and could provide
an independent measure of atherogenicity, which may be
superior to total cholesterol determination. However, only
a few studies evaluated the effect of oat intervention on
the size and concentration of lipoprotein particles, with
inconclusive results. More evidence is needed to establish
whether increased oat consumption favourably affects the
lipoprotein particle profile.
Blood pressure
Few studies found a significant effect of increased oat consump-
tion on blood pressure. However, none of the studies carried out
to date was adequately powered to rigorously evaluate the effect
of oats or oat bran on this outcome. Furthermore, blood pressure
results from these studies were most likely averaged from only
two or three consecutivemeasurements. Suchmethodology, rec-
ommended by the British Hypertension Society, might be useful
to identify hypertensive subjects but does not represent a precise
method for measuring blood pressure, as recently suggested(7).
Tighe et al.(7) found a significant reduction in systolic blood
pressure after 12 weeks intervention with whole grain (wheat
or oats plus wheat) compared with a refined cereals group.
Blood pressure was measured using additional consecutive
readings until the last three measurements varied by less than
8%, and a significant reduction would not have been identified
using the conventional method of measuring blood pressure.
This demonstrates the requirement for all types of intervention
trials (pharmaceutical, supplement, food-based, lifestyle inter-
ventions, etc.) where blood pressure is an outcome to adopt
procedures designed to accurately measure blood pressure
rather than those used for diagnostic classification. The best
method to accurately measure blood pressure is to carry out
24-h ambulatory measurements. Thus, adequately powered
and controlled intervention trials are required to determine
the effects of oats on blood pressure.
Glucose and insulin
Impaired fasting glycaemia and impaired glucose tolerance are
major risk factors for type 2 diabetes, and are strongly associ-
ated with an increased risk of CVD and all-cause mortality(93).
The present review indicates that interventions with oats or oat
bran do not affect fasting glycaemia or insulin concentration.
Table 2. Oats and blood lipids (studies with thirty to fifty-nine subjects in the oat intervention group)
Cholesterol
Comparison Total LDL HDL Total:HDL LDL:HDL TAG Reference
Low reporting quality
Kilned oats v. baseline (A)† NS – NS – – NS Kemppainen et al.(60)
Unkilned oats v. baseline (B) NS – NS – – 24%* #
0 v. 30 v. 60 v. 90g/d oat bran NS NS NS – – – Leadbetter et al.(61)
55 g high-fibre oat bran v. run-in NS NS 11%* " – 9%* # NS Mackay & Ball(62)
55 g low-fibre oat bran v. run-in NS NS 11%* " – 10%* # NS
Oat bran crispies v. no oat cereal 2% # 5% # NS NS NS NS Poulter et al.(63)
57 g/d instant oats v. usual intake 5%* # 5%* # NS – – NS Van Horn et al.(64)
NCEP and oat bran v. NCEP 6%* # 9%* # NS – – NS Winblad et al.(65)
NCEP and oat bran v. washout NS 9%* # NS – – NS
High reporting quality
Oats (high) v. oats, rice and wheat
(low) v. corn, rice and wheat bars
NS NS NS NS – NS Charlton et al.(66)
Oat bran v. wheat bran 6%* # 9%* # NS – – NS Kashtan et al.(68)
Uncooked whole oats v. baseline 5%* # 7%* # NS – – NS Katz et al.(72)
Oatbran v. wheat bran NS 6%* # NS – 9%* # NS Lepre & Crane(73)
Oat milk v. rice milk 6%* # 6%* # NS – NS NS Onning et al.(74)
Oatmeal and Oat Squares
v. wheat cereal and Kellogg’s Crispix
11%* # 12%* # NS – – NS Pins et al.(75)
Muesli with oat b-glucan v. wheat fibre 3% # 5% # NS 2% # – NS Theuwissen & Mensink(76)
Oats/soya and oats/milk
v. wheat/soya and wheat/milk
4%* # 6%* # NS – – – Van Horn et al.(78)
NCEP, National Cholesterol Education Program.
*% change from baseline relative to comparison group estimated.
†Group A started using kilned oats and group B started using unkilned oats.
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Similarly, evidence to date suggests that markers for insulin
resistance (homeostasis model assessment) or sensitivity
that use algorithms including fasted glucose and insulin
concentrations are also unchanged after intervention with
oats or oat bran.
Other outcomes
Many inflammatory markers (including C-reactive protein, IL-6
and soluble intercellular adhesion molecule 1 (ICAM-1)) have
been linked to CVD risk, but only high-sensitivity C-reactive
protein is currently considered an independent marker of
CVD risk(94). Observational studies suggest that a high dietary
fibre intake may reduce C-reactive protein levels(95,96). How-
ever, only a few intervention studies reported the effect of
long-term consumption of oats and oat bran on inflammatory
markers or markers of endothelial dysfunction (von Willeb-
rand factor, arterial stiffness and fibrinogen). None reported
changes in these markers with increased oat consumption,
suggesting that the benefits of oats on CVD are unlikely to
be mediated by the modulation of these markers. However,
more studies are needed to confirm the lack of effect, or other-
wise, of oats on these putative markers.
Other systemic compounds that have been linked to an
increased CVD risk include homocysteine(97), plasminogen
activator inhibitor-I(98) and factor VII(99). However, the studies
that examined the effects of increased oat consumption on
these markers are scarce. One study reported measuring
plasma homocysteine and found that concentrations
decreased by 16% in response to 12 weeks of oat bran(44).
A Danish study(33) found that plasminogen activator inhibi-
tor-I and factor VII levels decreased significantly by 27 and
7%, respectively, following a 2-week oat bran v. a low-fibre
diet. No other studies reported measuring these outcomes,
which deserve further investigation.
Weight gain is associated with an increased risk of high blood
pressure and hyperlipidaemia. Whilst some studies suggest that
increased oat consumption may aid weight loss(16,69) and
reduce waist circumference(82,84), the majority of studies
reviewed herein found no significant effect of oat consumption
on weight(15,17–20,22,24–26,28–30,33,36,38–40,42,45,48–50,52,55–58,
60–64,66–68,73–76,79,82–85,87,88), BMI(15,39–41,43,49,50,58,60,64,78,79,84)
or waist circumference(39,48–50). In order to assess the effect
of oats on body weight, it is necessary to also consider the
energy and macronutrient content of the intervention diets,
which is beyond the scope of the present review. Whilst
oats may be used to displace other (more energy dense)
foods in the diet, their effect on hunger and satiety is not
clear. Although three(48,67,86) of the studies included in the pre-
sent review found no significant effect of oats on satiety,
hunger or appetite, positive comments from one study(48)
included ‘feeling more full, for longer’ and ‘less peaks &
lows’ in intake. However, satiety is an acute physiological
effect of a single meal intake and does not necessarily
equate to longer-term changes in dietary habits, which could
result in weight loss and/or reduced weight gain. Therefore,
the measurement of satiety cannot substitute for longer-term
intervention studies measuring body weight and/or compo-
sition. The European Food Safety Authority Panel on Dietetic
Products, Nutrition and Allergies (NDA) recently concluded
that a cause-and-effect relationship has not been established
between the consumption of b-glucans from oats and barley
and a sustained increase in satiety leading to a reduction in
energy intake(100). However, this aspect requires further
investigation.
Whilst advice to increase oat consumption is likely to have
beneficial health effects, it should be noted that relatively
minor side effects (which may only be initial or intermittent)
may include flatulence(15,43,57,59,85), abdominal distension or
bloating(20,43,57,68,73), diarrhoea or loose stools(35,57,68), and
abdominal pain or cramping(48,57). Taking such side effects
into consideration, one study(43) found that 50 g/d of oat
bran was considered ‘acceptable long term’ by 76% of partici-
pants and ‘unacceptable long term’ by 24% of participants.
Table 3. Oats and blood lipids (studies with $60 subjects in the oat intervention group)
Cholesterol
Comparison Total LDL HDL Total:HDL LDL:HDL TAG Reference
Low reporting quality
Oat bran v. no added oat bran 4%* # 6%* # NS – – NS Berg et al.(79)
90 g/d oat cereal v. corn cereal 6%* # 8%* # NS – – NS Karmally et al.(80)
Oat bran cereal and CNA v. CNA NS NS NS NS – NS Keenan et al.(81)
Oat bran cereal v. baseline NS NS NS NS – NS
Oat cereal v. low-fibre foods 3% # 4% # NS – – NS Maki et al.(82)
Whole-wheat foods and oats v. whole-wheat foods NS NS NS – – NS Tighe et al.(7)
56 g oatmeal or no oat products NS NS NS – – NS Van Horn et al.(83)
100 g/d oatmeal v. wheat noodles 4%* # 5%* # 4%* " – – NS Zhang et al.(84)
High reporting quality
90 g oat cereal v. cornflakes 4% # 4% # NS – – NS Johnston et al.(85)
Oat bran cereal v. wheat cereal 6% # 8% # NS – – – Keenan et al.(86)
Oat bran v. no oat products NS – – – – – Van Horn et al.(87)
Oatmeal v. no oat products 3% # – – – – –
Oat bran v. oatmeal v. no oat products NS NS NS – – NS
Oat bran v. wheat bran cereal 4% # 6% # NS NS – NS Wolever et al.(88)
CNA, controlled-release nicotinic acid.
*% change from baseline relative to comparison group estimated.
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Limitations
The majority of studies identified by the present review were
relatively small and did not have sufficient power to detect an
effect: only twenty-three of the seventy-six articles reviewed
(30%) described carrying out a sample size or power calcu-
lation. For many of the variables (such as total cholesterol,
LDL-cholesterol, ICAM1, apo and glucose), variation among
individuals has been found by other authors to be about
10–20%. Baseline covariate adjustment should reduce this to
5–10%. This means that sixty subjects per group should
give sufficient experimental power (90%) to detect interven-
tion effects of 5–7%. Even less variation is expected in total
cholesterol (SD approximately 0·25mM, range 5–6mM), so
that sixty subjects per group will provide sufficient power to
detect differences of 0·2mM. Larger sample sizes would be
required to assess intervention effects on blood pressure and
inflammatory markers.
Ideally, a meta-analysis would be carried out to assess
whether oats have a significant effect on the outcomes
reported in the present review, and if so the size of this
effect. However, the authors concluded that a meaningful
summary estimate could not be obtained by meta-analysis
for several reasons. First, the studies were too heterogeneous.
The amount and type of oat products used were varied, and
the comparison/control groups included a range of different
treatments, for example, refined wheat, whole-wheat
products, rice bran, psyllium, farina, fruit or no control. The
duration of the studies (from 2 weeks to 6 months) and the
initial blood cholesterol concentration of the subjects were
also varied. Secondly, many studies were considered of poor
quality: 61% of articles had a low modified Jadad score, and
59% of studies had less than thirty subjects in the oat interven-
tion group. Thirdly, the outcomes were reported inconsist-
ently among studies, e.g. mean absolute difference, or
percentage change, or simply a line in the text to say that
there was no significant effect. Some changes were compared
with a control group v. baseline, and some results were
adjusted for confounding factors whereas others were not.
Furthermore, the present review did not consider the appro-
priateness of the control group, changes in body weight,
energy intake and macronutrient intake during the interven-
tion, or compliance with the intervention – all of which
could impact the response to the intervention and thus a
meta-analysis summary estimate. The question regarding
what could be considered as an ideal control group is
Table 4. Results of studies assessing the effect of oat consumption on blood pressure
Blood pressure
Comparison Systolic Diastolic Reference
,30 subjects in the oat intervention group and low reporting quality
Oat bran v. wheat bran (20 g fibre) NS NS Abrahamsson et al.(15)
65 g/8368 kJ/d (2000 kcal/d) oat bran bread v. 454 g/d strawberries NS NS Jenkins et al.(25)
Oat bran, oatmeal and oat b-glucan v. wheat-based, low-fibre
cereal and maltodextrin powder
NS NS Maki et al.(35)
45 g/d oats v. without 45 g/d oats 4%* # NS Saltzman et al.(41)
,30 subjects in the oat intervention group and high reporting quality
Oatmeal and oat bran v. wheat-based cereal NS NS Davy et al.(50)
137 g/d oat cereal v. 146g/d low-fibre cereal 6%* # NS Keenan et al.(55)
95 g/d oat bran v. 35 g/d wheat bran NS NS Kestin et al.(56)
95 g/d oat bran v. 60 g/d rice bran NS NS
100g/d oat bran v. refined wheat NS NS Swain et al.(57)
50 g/d oat bran v. baseline NS NS Uusitupa et al.(59)
30–59 subjects in the oat intervention group and low reporting quality
0 v. 30 v. 60 v. 90g/d oat bran NS NS Leadbetter et al.(61)
55 g high-fibre oat bran v. run-in NS NS Mackay & Ball(62)
55 g low-fibre oat bran v. run-in NS NS
$50 g/d Oat bran crispies v. no oat cereal NS NS Poulter et al.(63)
57 g/d instant oats v. usual intake NS NS Van Horn et al.(64)
30–59 subjects in the oat intervention group and high reporting quality
Oats (high) v. oats, rice and wheat (low) v. corn, rice and wheat NS – Charlton et al.(66)
OBC and Oatmeal Squares v. refined wheat and cornflakes NS NS He et al.(67)
60 g/d uncooked whole oats v. baseline NS NS Katz et al.(72)
60 g/d oat bran v. baseline NS NS Lepre & Crane(73)
Oat milk deprived of insoluble fibre v. rice milk NS NS Onning et al.(74)
Oatmeal and Oat Squares v. wheat cereal and Kellogg’s Crispix 4%* # NS Pins et al.(75)
Oats/soya and oats/milk v. wheat/soya and wheat/milk NS NS Van Horn et al.(78)
$60 subjects in the oat intervention group and low reporting quality
80 g/d oat cereal v. low-fibre foods NS NS Maki et al.(82)
Whole-wheat foods and oats v. whole-wheat foods NS NS Tighe et al.(7)
100 g/d oatmeal v. wheat noodles NS NS Zhang et al.(84)
$60 subjects in the oat intervention group and high reporting quality
90 g oat cereal v. cornflakes NS NS Johnston et al.(85)
20 g/d oat bran cereal v. 21g/d wheat bran cereal NS NS Wolever et al.(88)
OBC, oat bran concentrate.
*% change from baseline relative to comparison group estimated.
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important, and depends on the study aim as well as the
primary outcomes of the trial. The results tables highlight
the disparity of control groups used as comparators in pre-
vious studies. Guar gum, undefined control diet, usual diet,
wheat- or rice-based products, b-glucan-enriched products
as well as products based on specific parts of the grain such
as bran and not the whole-grain product have been used.
Some designs involved increasing total whole-grain intake
without substitution of existing dietary components. An ideal
control group should at least consider unchanged total
energy intake during the intervention, substituting whole-
grain food items with a similar amount of refined cereal
products (white breads, etc.). The level of oats/whole-grain
intake in the control group should match the lowest quartile
of consumption observed in the population studied.
When trials aim to identify the active parts or components of
the grain, a positive control (with whole grain) should also
be included. Further analysis of the studies reviewed herein
is required before sufficiently homogenous studies can be
chosen for inclusion in a meta-analysis to obtain both a
precise and meaningful estimate of the magnitude of the
effect of oat consumption on CVD risk markers.
The lack of significant effects in some studies may have
been due to the factors mentioned earlier, or could be due
to the fact that the response may be modified by other factors.
Some studies carried out sub-group analysis or tested for
interaction (effect modification), e.g. by sex(29,37,38,52,83), sex
and age group(86), BMI group(35), ethnicity (Caucasians v.
non-Caucasians)(89), genotype(59,69), amount of target dose
consumed(59) and baseline total cholesterol level(40,83).
Table 5. Results of studies assessing the effect of oat consumption on glucose and insulin
Comparison Glucose Insulin Reference
,30 subjects in the oat intervention group and low reporting quality
Oat bran v. wheat bran (20 g fibre) NS NS Abrahamsson et al.(15)
100 g/d oat bran v. control diet NS – Anderson et al.(16)
Oat bran bread v. wheat bran bread NS NS Bremer et al.(20)
40 g/d oat bran diet v. low-fibre diet v. – NS Dubois et al.(23)
100 g/d oat bran v. no oat bran NS – Kirby et al.(30)
Oat bran, oatmeal and oat b-glucan v. wheat-based,
low-fibre cereal and maltodextrin powder
NS NS Maki et al.(35)
87–121g/d oat bran v. 50–74 g/d high-amylose starch diet NS NS Noakes et al.(37)
87–121g/d oat bran v. low-amylose starch diet 3%* " NS
0·75–1 l/d oat milk v. cow’s milk NS NS Onning et al.(38)
0·75–1 l/d oat milk v. soya milk NS NS
45 g/d oats v. without 45 g/d oats NS NS Saltzman et al.(41)
123 g/d oat bran v. 54g/d wheat bran NS – Whyte et al.(46)
,30 subjects in the oat intervention group and
high reporting quality
5–6 g/d oat bran b-glucan v. 8–9 g/d oat bran
b-glucan v. high fibre, no oat bran b-glucan
NS NS Beck et al.(48)
Oatmeal and oat bran v. wheat-based cereal NS NS Davy et al.(49,50)
60 g/d oat cookies v. baseline NS NS Conceicao de Oliveira et al.(51)
60 g/d oat cookies v. 300g/d fruit 5%* " –
High molecular weight oat bran
v. baseline
3%* # 23%* " Frank et al.(52)
Low molecular weight oat bran
v. baseline
NS NS
137g/d oat cereal v. 146g/d low-fibre cereal – NS Keenan et al.(55)
95 g/d oat bran v. 35 g/d wheat bran NS NS Kestin et al.(56)
95 g/d oat bran v. 60 g/d rice bran NS NS
50/d oat bran v. baseline þ4%* " NS Uusitupa et al.(59)
30–59 subjects in the oat intervention group and
low reporting quality
No studies
30–59 subjects in the oat intervention group and
high reporting quality
Oats (high) v. oats, rice and wheat (low)
v. corn, rice and wheat
NS NS Charlton et al.(66)
Oat milk deprived of insoluble
fibre v. rice milk
NS – Onning et al.(74)
Oatmeal and Oat Squares v. wheat cereal and Kellogg’s Crispix 13%* # – Pins et al.(75)
$60 subjects in the oat intervention group and
low reporting quality
Whole wheat foods and oats
v. whole wheat foods
NS NS Tighe et al.(7)
100 g/d oatmeal v. wheat noodles NS – Zhang et al.(84)
$60 subjects in the oat intervention group and
high reporting quality
20 g/d oat bran cereal v. 21g/d wheat bran cereal NS – Wolever et al.(88)
*% change from baseline relative to comparison group estimated.
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The results of such analyses were not considered in the pre-
sent review; however, these need to be further assessed in
larger studies with sufficient power for subgroup analyses or
assessing effect modification.
The present review only considered the effect of oats on
fasting lipids, glucose and insulin. However, regular consump-
tion of oats may alter the postprandial concentrations. For
example, Anderson et al.(18) showed that 110 g/d oat bran
for 21 d significantly lowered postprandial serum total choles-
terol and TAG concentrations v. a control diet. However, Kirby
et al.(30) found that a similar amount of oat bran (100 g/d) for
a shorter time period (at least 10 d) did not significantly affect
postprandial serum total cholesterol or TAG, when measured
at hourly intervals throughout the day when compared with
a control diet. A 12-week trial of oat consumption significantly
lowered the mean peak insulin and incremental area under
the insulin curve response (both by 7%) compared with a
control group, but there was no significant change in peak
glucose or incremental area under the glucose curve(35).
Other studies found that oats or oat bran did not significantly
affect postprandial glucose or insulin responses(30,34,56). The
efficacy of oats and barley products to lower postprandial
blood glucose concentration has been reviewed recently(13).
The author concluded that intact grain, as well as barley and
oat products containing at least 4 g of b-glucan and 30–80 g
of available carbohydrate can significantly reduce postprandial
glucose concentrations. The health benefit of reducing post-
prandial glycaemia is still debatable, but a statement recently
issued by the European Food Safety Authority indicates that
‘the reduction of postprandial glycaemic responses (as long
as insulinaemic responses are not disproportionally increased)
may be a beneficial physiological effect’(100).
Conclusions
Regular consumption of oats or oat bran has a beneficial effect
on total cholesterol and LDL-cholesterol, particularly in
hypercholesterolaemic subjects. The intervention trials
described in the present review can generally be divided
into three groups depending on the product used in the inter-
vention: oat bran; whole-grain oat cereals; oatmeal. For the
studies that showed a significant reduction in total cholesterol
and/or LDL-cholesterol, the range of doses used was
25–135 g/d for oat bran, 45–90 g/d for whole-grain oat cereals
and 60–150 g/d for oatmeal. So it appears that the form of oats
does not really affect the outcome. The doses required to
reach a significant effect were also similar. However, studies
using amounts below 50 g/d are scarce, and more well-
designed dose–response studies are needed to confirm the
minimum amount required to have a clinical beneficial
effect. The 3–6% cholesterol reduction described in the
larger studies would translate to a 6–18% decrease in CHD
risk. Some studies reported significant effects on blood choles-
terol only 2 weeks after beginning the intervention, so it is
likely that the benefits of increasing oats intake start very
shortly after changing the diet. How long these effects on
blood cholesterol remain if subjects revert to their original
diet remains to be determined. However, there is no indication
that it would significantly modulate insulin sensitivity. It is still
unclear whether increased oat consumption would
significantly affect other risk markers for CVD risk. More
comprehensive, properly controlled intervention trials with
adequate sample sizes are required to answer this question.
The present review also highlighted the heterogeneity of
treatments used as a control and notes the importance of care-
fully defining appropriately controlled interventions.
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